SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Techniclone (TCLN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: True Grit who wrote (2952)3/12/1999 9:06:00 AM
From: shero  Read Replies (1) of 3702
 
True Grit:

I don't know where you heard all that stuff about the Lym-1 trials. My info has it the we are less (way less) the 50% of enrollment. And because of the terrible protocol accepted by Alpha and TCLN the first 15 or so patients were too sick. I think most of them only received imaging doses before...well, we know what happens to high grade lympnoma patients.

But at least that protocol was modified and now we can treat patients who have failed other MaB therapies.

I am going to try to focus on the positive, oh, it is so hard after all these years, your point is well taken. Try on these glasses. Schering has had a chance to review all the LYM data. They coughed up $3MM, granted that is a rounding error to them, but these companies still don't throw away money. I feel Schering must think this is an approvable drug.

And it does provide credibility. The 'Street' clearly didn't think a deal would get done, lets see if any institutions are willing to hear the "new" story.

And your comments are, as always, welcome.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News